Revolution Medicines Inc. has begun treating patients in a phase 3 clinical trial evaluating daraxonrasib as a first-line treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE